Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K DATED AUGUST 23, 2012 - UROLOGIX INC | urologix123485_8k.htm |
| EX-99.1 - PRESS RELEASE ISSUED AUGUST 23, 2012 - UROLOGIX INC | urologix123485_ex99-1.htm |
Exhibit 99.2
Urologix, Inc.
Certain Remarks of Brian J. Smrdel
4th Quarter FY 2012 Earnings Call
August 23, 2012
| · | [International sales of Prostiva represent] only 4-5% of our total Company sales on an annualized basis [for fiscal year 2012]. |
| · | Third party mobile operations represent approximately 10% of fiscal year 2012 sales. |
| · | Urologix direct channel represents the remaining 85% of our total Company sales [for fiscal year 2012]. |
| · | Urologix direct sales were comprised of roughly one-third CTT, one-third Prostiva and one-third mobile services in fiscal year 2012. |
| · | Prostiva revenue was $1.7 million [for fourth quarter fiscal year 2012]. |
| · | Payments for approximately $1.7 million of Prostiva product received during the fourth quarter of fiscal year 2012, and $3.8 million for the year-to-date period, were deferred as a result of 270-day payment terms. |